A Novel Broad-Host-Range Phage for Treatment of Mouse Model of Escherichia coli Urinary Tract Infection

Suhad Y. Abed*, Ali H. Alsakini, Manal K. Mohammad, Sundus Q. Mohammed, Sadeq A.G. Kaabi

Biology Department- College of Science- Mustansiriyah University- Baghdad- Iraq

Corresponding Author: [email protected]; Tel: 009647709023245
Recieved Date: 28 August 2021; Accepted Date: 01 April 2022; Published Date: 03 May
Citation: Abed SY, Alsakini AH, Mohammad MK, Mohammed SQ, Kaabi SAG. A Novel Broad-Host-Range Phage for Treatment of Mouse Model of Escherichia coli Urinary Tract Infection. Trop J Nat Prod Res. 2022; 6(4): 488-493 http://www.doi.org/10.26538/tjnpr/v6i4.6
© 2022 Abed et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at  Tropical Journal of Natural Product Research


The increasing emergence of drug resistance in pathogens of urinary tract infections (UTIs) has resulted in a pressing need to develop new approaches to control this infection. This study is aimed at isolating broad-host-range phage active against isolates of uropathogenic Escherichia coli and other bacterial pathogens causing UTIs and to study its therapeutic potential on mouse model of chronic UTIs. The broad-host-phage was isolated through enrichment of E. coli isolates with sewage water and detected by spot lysis method, growth inhibition assay and top plaque assay. A novel broad-host-range phage, PEC34, was isolated and showed a 100% lytic activity towards UPEC, whereas other isolated phages showed a 12-30% lytic activity. The phage PEC34 showed lytic activity against Gram-negative pathogens of UTI like Proteus mirabilis, Citrobacter freundii, Klebsiella oxytoca and Enterobacter cloacae, but showed no lytic activity against Pseudomonas aeruginosa nor Staphylococcus aureus. The phage therapy of mouse model of chronic UTI by the broad-host-range phage PEC34 through transurethral and intraperitoneal injection of 100 µL (1011 plaque forming units (PFU) of phage preparation on day 10 after the establishment of the infection resulted in clearance of pathogenic bacteria from the urine of mice and homogenates of bladders and kidneys of sacrificed mice after only 24 h, whereas therapy by a narrow host-range phage PEC80 showed no such effects. The phage P34 could be a strong candidate for treatment of UTIs and other infections caused by bacteria sensitive to lytic action of the phage.

Keywords: Phage therapy, Urinary tract infections, broad-host-range phage, Chronic UTI mouse model, Alternative therapy.
Back to Articles

ISSN: 2616-0684 (Print)
ISSN: 2616-0692 (Online)
DOI: 10.26538/tjnpr
Index Copernicus Value (ICV) for 2017: 59.83
Scopus citescore 0.3 (2020)

Indexing & Abstracting

citescore 0.3 (2020)

j-gate logo

International Innovative Journal Impact Factor

African Index Medicus


Index Copernicus International

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

Crossref Content Registration logo

WorldCat Discovery Service

Geneva Foundation for Medical Education and Research